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Background
The search for synergistic drug combinations is critical to
the treatment of drug resistant cancers, such as acute
myelogenous leukemia (AML), which has 50% to
60% overall survival in children and lower in adults [1].
Conventional treatments include the S phase-specific
polymerase II inhibitor 1-h-D-Arabinofuranosylcytosine
(ARA-C), but DNA methyltransferase inhibitors such as
5-Aza-2´-deoxycytidine (DAC) also have activity in AML,
through DNA genomic demethylation and altered gene
expression [2]. Although genome-wide changes in RNA
expression associated with DAC and ARA-C are not fully
understood [3], characterizing these responses is a critical
step to increasing the efficacy of combinatorial therapies
that include DAC and ARA-C.
Materials and methods
RNA expression levels were assessed using the Human
Exon 1.0ST (Affymetrix) array 72 hours after single-dose
treatments with 1.0 µM DAC or ARA-C in UT7epo,
Molm13, and NB4 cells. The half maximal effective con-
centration (EC50) of DAC and ARA-C was determined
in each cell line, and the drug combination index (CI)
was calculated using the Chou-Talalay method.
Results
While increased RRM2 expression is observed following
ARA-C exposure and is associated with ARA-C resistance
in UT7epo cells, pre-treatment with DAC restores cellular
sensitivity and correlates with increased RNA expression
of the nucleoside transporter, SLC29A1/hENT1. In
contrast, DAC/ARA-C combinations are antagonistic in
Molm13 cells, where each drug independently increases
RNA expression of C-KIT and associated proliferation
pathways.
Conclusions
Pre-treatment with DAC can sensitize ARA-C resistant
AML cells, but can increase resistance in ARA-C sensitive
AML cells. Possible molecular mechanisms for these results
are suggested by the transcriptional response to DAC.
These results show that responses to drug combinations
are driven by the molecular responses of individual cell
types. The results also provide an alternative approach for
predicting what combinations, dosing and scheduling of
drug delivery should be used to better individualize therapy.
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